These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36914577)

  • 21. Conformational and Thermodynamic Landscape of GPCR Activation from Theory and Computation.
    Dong SS; Goddard WA; Abrol R
    Biophys J; 2016 Jun; 110(12):2618-2629. PubMed ID: 27332120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.
    Sanchez-Soto M; Verma RK; Willette BKA; Gonye EC; Moore AM; Moritz AE; Boateng CA; Yano H; Free RB; Shi L; Sibley DR
    Sci Signal; 2020 Feb; 13(617):. PubMed ID: 32019899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.
    Staus DP; Strachan RT; Manglik A; Pani B; Kahsai AW; Kim TH; Wingler LM; Ahn S; Chatterjee A; Masoudi A; Kruse AC; Pardon E; Steyaert J; Weis WI; Prosser RS; Kobilka BK; Costa T; Lefkowitz RJ
    Nature; 2016 Jul; 535(7612):448-52. PubMed ID: 27409812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor.
    Chen Y; Fleetwood O; Pérez-Conesa S; Delemotte L
    J Chem Inf Model; 2021 Dec; 61(12):6024-6037. PubMed ID: 34780174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.
    Seifert R; Wenzel-Seifert K; Gether U; Kobilka BK
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1218-26. PubMed ID: 11356949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligand-binding affinity of alternative conformers of human β
    Dilcan G; Doruker P; Akten ED
    Chem Biol Drug Des; 2019 May; 93(5):883-899. PubMed ID: 30637937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G protein-coupled receptors--recent advances.
    Latek D; Modzelewska A; Trzaskowski B; Palczewski K; Filipek S
    Acta Biochim Pol; 2012; 59(4):515-29. PubMed ID: 23251911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying multiple active conformations in the G protein-coupled receptor activation landscape using computational methods.
    Dong SS; Goddard WA; Abrol R
    Methods Cell Biol; 2017; 142():173-186. PubMed ID: 28964335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational complexity of G-protein-coupled receptors.
    Kobilka BK; Deupi X
    Trends Pharmacol Sci; 2007 Aug; 28(8):397-406. PubMed ID: 17629961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Energy Landscapes Reveal Agonist Control of G Protein-Coupled Receptor Activation via Microswitches.
    Fleetwood O; Matricon P; Carlsson J; Delemotte L
    Biochemistry; 2020 Feb; 59(7):880-891. PubMed ID: 31999436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular determinants of ligand efficacy and potency in GPCR signaling.
    Heydenreich FM; Marti-Solano M; Sandhu M; Kobilka BK; Bouvier M; Babu MM
    Science; 2023 Dec; 382(6677):eadh1859. PubMed ID: 38127743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accurate Binding Configuration Prediction of a G-Protein-Coupled Receptor to Its Antagonist Using Multicanonical Molecular Dynamics-Based Dynamic Docking.
    Bekker GJ; Araki M; Oshima K; Okuno Y; Kamiya N
    J Chem Inf Model; 2021 Oct; 61(10):5161-5171. PubMed ID: 34549581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. β2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases.
    Matera MG; Page C; Rinaldi B
    Curr Opin Pharmacol; 2018 Jun; 40():142-146. PubMed ID: 29763833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
    Saleh N; Ibrahim P; Clark T
    Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structures of β
    Su M; Paknejad N; Zhu L; Wang J; Do HN; Miao Y; Liu W; Hite RK; Huang XY
    Nat Commun; 2022 Jul; 13(1):4095. PubMed ID: 35835792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor.
    Woo AY; Song Y; Zhu W; Xiao RP
    Br J Pharmacol; 2015 Dec; 172(23):5477-88. PubMed ID: 25537131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand induced change of β2 adrenergic receptor from active to inactive conformation and its implication for the closed/open state of the water channel: insight from molecular dynamics simulation, free energy calculation and Markov state model analysis.
    Bai Q; Pérez-Sánchez H; Zhang Y; Shao Y; Shi D; Liu H; Yao X
    Phys Chem Chem Phys; 2014 Aug; 16(30):15874-85. PubMed ID: 24962153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling GPCR active state conformations: the β(2)-adrenergic receptor.
    Simpson LM; Wall ID; Blaney FE; Reynolds CA
    Proteins; 2011 May; 79(5):1441-57. PubMed ID: 21337626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fragment-Based Computational Method for Designing GPCR Ligands.
    Li Y; Sun Y; Song Y; Dai D; Zhao Z; Zhang Q; Zhong W; Hu LA; Ma Y; Li X; Wang R
    J Chem Inf Model; 2020 Sep; 60(9):4339-4349. PubMed ID: 31652060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models.
    Vilar S; Ferino G; Phatak SS; Berk B; Cavasotto CN; Costanzi S
    J Mol Graph Model; 2011 Feb; 29(5):614-23. PubMed ID: 21146435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.